RNS Number : 0346F
Genedrive PLC
04 March 2020

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to members of its senior management team to acquire a total of 2,169,608 ordinary shares of 1.5p each ("Ordinary Shares") in the Company under the Company's Share Option Scheme.

The Options have been granted with an exercise price equal to the close price on the day before the grant and vest after a period of three years, subject to certain performance criteria being met through achieving revenue targets, achieving cash targets and completing certain strategic projects in the year ending June 2022. The Options are exercisable over the period of 10 years from the date of grant.

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1.	***Details of the person discharging managerial responsibilities / person closely associated***	
a.	*Name*	***1. David Budd*** ***2. Matthew Fowler*** ***3. Gino Miele*** ***4. Gordon Powell*** ***5. Colleen Pythian***
2.	***Reason for the notification***	
a.	*Position/status*	***1.*** *CEO* ***2.*** *CFO* ***3.*** *R&D Director* ***4.*** *Commercial Director* ***5.*** *Director of Quality & Regulation*
a.	*Initial notification /Amendment*	*Initial notification*
3.	***Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor***	
a.	*Name*	*genedrive plc*
b.	*LEI*	*213800ZYODIRZ87Y4K14*
4.	***Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted***	

<table>
<tr><td>a.</td><td>Description of the Financial instrument, type of instrument Identification code</td><td>Options over ordinary shares of 1.5 pence each

GB00B1VKB244</td></tr>
<tr><td>b.</td><td>Nature of the transaction</td><td>Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017</td></tr>
<tr><td>c.</td><td>Price(s) and volume(s)</td><td>
<table>
<tr><th>Option price(s)</th><th>Volume(s)</th><th></th></tr>
<tr><td>David Budd</td><td>9.0p</td><td>1,056,982</td></tr>
<tr><td>Matthew Fowler</td><td>9.0p</td><td>672,626</td></tr>
<tr><td>Gino Miele</td><td>9.0p</td><td>170,000</td></tr>
<tr><td>Gordon Powell</td><td>9.0p</td><td>170,000</td></tr>
<tr><td>Colleen Pythian</td><td>9.0p</td><td>100,000</td></tr>
</table>
</td></tr>
<tr><td>d.</td><td>Aggregated information
· Aggregated volume
· Price</td><td>N/A</td></tr>
<tr><td>e.</td><td>Date of the transaction</td><td>2020-04-03</td></tr>
<tr><td>f.</td><td>Place of the transaction</td><td>Outside a trading venue</td></tr>
</table>

For further details please contact:

genedrive plc +44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker) +44 (0)20 7418 8900
James Steel / Oliver Jackson

Stanford Capital Partners Limited (Joint Broker) +44 (0)20 3815 8880
Patrick Claridge / John Howes

Walbrook PR Ltd (Media Relations & Investor Relations) +44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876 741 001

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

DSHJIMATMTJMBBM